Cubist Systematic Strategies LLC Acquires 79,655 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Cubist Systematic Strategies LLC increased its position in REGENXBIO Inc. (NASDAQ:RGNX) by 73.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 188,235 shares of the biotechnology company’s stock after acquiring an additional 79,655 shares during the period. Cubist Systematic Strategies LLC’s holdings in REGENXBIO were worth $2,202,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Perceptive Advisors LLC bought a new stake in shares of REGENXBIO in the fourth quarter worth $6,146,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of REGENXBIO by 80.3% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 170,218 shares of the biotechnology company’s stock worth $3,586,000 after acquiring an additional 75,800 shares during the period. Integral Health Asset Management LLC grew its holdings in shares of REGENXBIO by 25.0% in the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock worth $11,115,000 after acquiring an additional 190,000 shares during the period. Virtu Financial LLC bought a new stake in shares of REGENXBIO in the fourth quarter worth $377,000. Finally, Quest Partners LLC grew its holdings in shares of REGENXBIO by 11,731.0% in the second quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company’s stock worth $491,000 after acquiring an additional 41,645 shares during the period. Institutional investors own 88.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Barclays cut their price target on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, August 5th. The Goldman Sachs Group started coverage on REGENXBIO in a research report on Friday, June 7th. They issued a “buy” rating and a $38.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $39.00 target price on shares of REGENXBIO in a research note on Wednesday, September 4th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.91.

Insiders Place Their Bets

In other news, CEO Curran Simpson sold 9,648 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $15.04, for a total transaction of $145,105.92. Following the sale, the chief executive officer now directly owns 170,137 shares in the company, valued at approximately $2,558,860.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Curran Simpson sold 9,648 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $15.04, for a total transaction of $145,105.92. Following the transaction, the chief executive officer now owns 170,137 shares of the company’s stock, valued at approximately $2,558,860.48. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $11.56, for a total value of $115,600.00. Following the completion of the sale, the director now owns 11,286 shares of the company’s stock, valued at $130,466.16. The disclosure for this sale can be found here. Insiders sold 55,279 shares of company stock valued at $762,934 in the last three months. Corporate insiders own 13.13% of the company’s stock.

REGENXBIO Trading Down 2.9 %

Shares of REGENXBIO stock opened at $10.49 on Tuesday. The firm has a market cap of $516.70 million, a PE ratio of -1.78 and a beta of 1.22. The stock has a 50 day moving average of $12.27 and a 200 day moving average of $14.45. REGENXBIO Inc. has a 12 month low of $10.14 and a 12 month high of $28.80.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.24. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. The firm had revenue of $22.30 million during the quarter, compared to the consensus estimate of $22.97 million. During the same period in the prior year, the company earned ($1.66) EPS. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. As a group, equities research analysts forecast that REGENXBIO Inc. will post -4.66 earnings per share for the current fiscal year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.